Athenex, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for cancer. Its proprietary platform, which includes the use of its drug delivery technology, sets it apart in the oncology market, particularly in the U.S. and China.
Business Overview
Athenex generates revenue primarily through the sale of its proprietary cancer therapies, leveraging its unique drug delivery technology to enhance efficacy and reduce side effects. The company also monetizes its research through partnerships and licensing agreements, providing a diversified revenue stream.
FDA approval of new oncology drugs, particularly those utilizing its proprietary delivery technology
Partnership announcements with larger pharmaceutical companies for drug development
Market adoption rates of existing therapies in the U.S. and China
Changes in reimbursement policies affecting oncology treatments
Risk Factors
Regulatory changes that could impact drug approval processes
Technological advancements by competitors that could render Athenex's products less competitive
Increased competition from generic drug manufacturers
Emerging biotech firms with innovative cancer therapies
Negative operating cash flow leading to liquidity concerns
High reliance on future funding rounds to sustain operations
Macro Sensitivity
moderate - The demand for healthcare services and pharmaceuticals tends to be less sensitive to economic cycles, but funding for R&D can be affected by broader economic conditions.
Higher interest rates could increase the cost of capital for Athenex, impacting its ability to finance R&D projects and potentially slowing down drug development timelines.
minimal - Athenex has a negative debt/equity ratio, indicating a lack of reliance on debt financing.
Profile
growth - Investors looking for high-risk, high-reward opportunities in the biotech sector.
high - The stock has experienced significant volatility, with a 1-year return of -98.1%.
Explore More
Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
